NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | -3.57% |
|
-10.00% | +1.12% |
06-07 | NeurAxis Submits Application to FDA to Expand IB-Stim Label | MT |
05-22 | Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635 | MT |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.12% | 17.95M | |
+75.69% | 12.57B | |
+11.24% | 6.92B | |
-30.25% | 6.8B | |
+11.54% | 5.32B | |
-20.60% | 4.63B | |
+10.66% | 3.94B | |
-22.90% | 3.86B | |
-28.90% | 2.68B | |
+28.43% | 2.06B |
- Stock Market
- Equities
- NRXS Stock
- News NeurAxis, Inc.
- Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025